Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10671585 | 0.70 | KMT2A (0.34) | POLBNPC1RAB9ASMN1; SMN2AR | |
| SCHEMBL6475145 | 0.69 | DDB1 (0.41) | POLBNPC1RAB9ASMN1; SMN2AR | |
| SCHEMBL10375560 | 0.67 | WDR5 (0.33) | NPC1RAB9AHDAC6KCNN3AR | |
| SCHEMBL10575979 | 0.66 | PDE10A (0.36) | POLBKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL4156000 | 0.64 | CYP2D6 (0.55) | MAPT | |
| SCHEMBL29989874 | 0.63 | MEN1 (0.50) | POLBKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28650482 | 0.63 | MEN1 (0.50) | POLBKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2674802 | 0.58 | HTR2B (0.55) | POLBKDM4ENPC1RAB9AKMT2A | |
| SCHEMBL6756134 | 0.58 | NPC1 (0.59) | POLBKDM4ENPC1RAB9AKMT2A | |
| SCHEMBL2276872 | 0.58 | ALDH1A1 (0.59) | POLBKDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | POLB 518/4885KDM4E 1518/4885NPC1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.